Alzheimer's Drug Slows Decline, Trial Data Show
Lecanemab met primary and secondary endpoints, but was associated with adverse events
Stay updated with breaking news from Sam Gandy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lecanemab met primary and secondary endpoints, but was associated with adverse events
WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- The experimental Alzheimer’s drug lecanemab slowed thinking declines among patients suffering the early stages of the disease in a new study, but safety concerns about brain swelling and brain bleeds remain.
Medically reviewed by Dr. Ari Magill First described by Alois Alzheimer in 1906, Alzheimer's disease (AD) is a ...
Gum disease has far-reaching effects and may increase your odds of developing dementia, a new study suggests. In ...
THURSDAY, Sept. 22, 2022 (HealthDay News) -- No one likes nightmares, but having persistently bad dreams may also signal impending dementia, new British research suggests.